5 results on '"Li, Liu‐Cheng"'
Search Results
2. Chinese herbal injections for coronavirus disease 2019 (COVID-19): A narrative review
- Author
-
Zhu, Xiao-Bin, Guo, Meng, Zhang, Zhi-Hui, Sun, Li-Hua, Liu, Lei, Zhou, Li-Juan, Shan, Chun-Lei, Yang, Yi, Kan, Lian-Di, and Li, Liu-Cheng
- Published
- 2021
- Full Text
- View/download PDF
3. Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects.
- Author
-
Li, Liu-Cheng and Kan, Lian-Di
- Subjects
- *
INFLAMMATION prevention , *PULMONARY fibrosis , *ALKALOIDS , *ALTERNATIVE medicine , *CELLULAR signal transduction , *DRUG design , *FLAVONOIDS , *GLYCOSIDES , *HERBAL medicine , *MEDICINAL plants , *CHINESE medicine , *MEDLINE , *ONLINE information services , *SYSTEMATIC reviews , *EVIDENCE-based medicine , *PLANT extracts , *PROFESSIONAL practice , *OXIDATIVE stress , *PREVENTION - Abstract
Ethnopharmacological relevance Pulmonary fibrosis (PF) is a chronic, debilitating and often lethal lung disorder. Despite the molecular mechanisms of PF are gradually clear with numerous researchers’ efforts, few effective drugs have been developed to reverse human PF or even halt the chronic progression to respiratory failure. Traditional Chinese medicine (TCM), the main component of the medical practice used for more than 5000 years especially in China, often exerts wider action spectrum than previously attempted options in treating human diseases. Recent data have shown the anti-fibrotic benefits of the active ingredients from TCM in this field, which may represent an attractive source of the drug discovery against PF. Aim of the review This review summarizes the pre-clinical and clinical evidence on the benefits of TCM and their active ingredients, and provides a comprehensive information and reliable basis for the exploration of new treatment strategies of botanical drugs in the therapy of PF. Methods The literature information was obtained from the scientific databases on ethnobotany and ethno medicines (up to Aug 2016), mainly from the Pubmed, Web of Science and CNKI databases, and was to identify the experimental studies on the anti-fibrotic role of the active agents from TCM and the involved mechanisms. The search keywords for such work included: “lung fibrosis” or “pulmonary fibrosis”, and “traditional Chinese medicine”, “extract” or “herb”. Results A number of studies have shown that the active agents of single herbs and TCM formulas, particularly the flavonoids, glycosides and alkaloids, exhibit potential benefits against PF, the mechanisms of which appear to involve the regulation of inflammation, oxidant stress, and pro-fibrotic signaling pathways, etc . Besides, the processing methods for discovering TCM in treating PF were prospectively discussed. Conclusion These research work have shown the therapeutic benefits of TCM in the treatment of PF. However, more continued researches should be undertaken to clarify the unconfirmed chemical composition and regulatory mechanisms, conduct standard clinical trials, and evaluate the possible side effects. The insights provided in present review will be needed for further exploration of botanical drugs in the development of PF therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: Advances and prospects.
- Author
-
Li, Liu-Cheng, Zhang, Zhi-Hui, Zhou, Wen-Cheng, Chen, Jie, Jin, Hua-Qian, Fang, Hong-Mei, Chen, Qin, Jin, Ye-Cheng, Qu, Jiao, and Kan, Lian-Di
- Subjects
- *
COVID-19 , *DISEASE outbreaks , *VIRUS diseases , *SARS-CoV-2 - Abstract
• COVID-19 has led to serious death and lacks treatment strategies. • Lianhua Qingwen is a commonly used Chinese patent medicine to treat viral infection. • Lianhua Qingwen has antiviral, anti-inflammatory and immunoregulatory activities. • Lianhua Qingwen combined with conventional treatment obviously improved COVID-19. • Lianhua Qingwen can be a complementary strategy for treating COVID-19. An outbreak of Coronavirus Disease 2019 (COVID-19) which was infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is still spreading and has led to unprecedented health emergency over the world. Though no specific drug has been developed so far, emerging agents have been confirmed effective or potentially beneficial to restrain it. Lianhua Qingwen (LHQW) is a commonly used Chinese medical preparation to treat viral influenza, including in the fight against SARS in 2002–2003 in China. Recent data also showed that LHQW played a vigorous role in COVID-19 treatment. This review will elucidate the pre-clinical and clinical evidence of LHQW in lung protection and antiviral activities, and provide timely data delivery for the exploration of effective treatment strategies in the therapy of COVID-19. The research data were obtained from the academic databases (up to August 8, 2020) including Pubmed, CNKI and Web of Science, on ethnobotany and ethno medicines. The search keywords for screening the literature information were "virus", "COVID-19", or "SARS-CoV-2", and "Lianhua Qingwen". The documents were filtered and summarized for final evaluation. The collected evidence demonstrated that LHQW exhibited benefits against COVID-19. Impressively, LHQW in conjunction with conventional treatment could significantly improve COVID-19 patients as a synergetic strategy. The mechanisms were mainly involved the antiviral activity, and regulation of inflammation response as well as immune function. Although the data were far from adequate, the latest advances had shown the benefits of LHQW in COVID-19, especially in combination with other antiviral drugs. This review provides comprehensive evidence of LHQW as a complementary strategy for treating COVID-19. Nevertheless, imperious researches should be conducted to clarify the unconfirmed effects, regulatory mechanisms and adverse reactions of LHQW in treating COVID-19 by means of well designed randomized controlled trials. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Inositol-requiring protein 1 – X-box-binding protein 1 pathway promotes epithelial–mesenchymal transition via mediating snail expression in pulmonary fibrosis.
- Author
-
Mo, Xiao-Ting, Zhou, Wen-Cheng, Cui, Wen-Hui, Li, De-Lin, Li, Liu-Cheng, Xu, Liang, Zhao, Ping, and Gao, Jian
- Subjects
- *
PULMONARY fibrosis , *BLEOMYCIN , *ENDOPLASMIC reticulum , *TRANSFORMING growth factors , *ZINC-finger proteins , *TRANSCRIPTION factors , *CELLULAR signal transduction , *LABORATORY rats - Abstract
Epithelial–mesenchymal transition (EMT) is a complex biological program during which cells loss epithelial phenotype and acquire mesenchymal features. EMT is thought to be involved in the pathogenesis of various fibrotic diseases including pulmonary fibrosis (PF). Recent studies suggest that endoplasmic reticulum (ER) stress is associated with EMT in the progression of PF. However, the exact mechanism is unclear. Here, we developed a PF model with bleomycin (BLM) administration in rats and conducted several simulation experiments in alveolar epithelial cell (AECs) RLE-6TN to unravel the role of inositol-requiring protein 1 (IRE1) – X-box-binding protein 1 (XBP1) signal pathway in ER stress-induced EMT in PF. First, we observed that ER stress was occurred in type II AECs accompanied by EMT in BLM-induced PF. Then we explored the role of IRE1-XBP1-snail pathway in transforming growth factor (TGF)-β1/tunicamycin (TM)-induced EMT. When TGF-β1/TM was treated on AECs, IRE1 and XBP1 were overexpressed, meanwhile, snail expression was upregulated accompanied with EMT. However, when IRE1 or XBP1 was knockdown, TGF-β1/TM-induced EMT were blocked while the expression of snail was inhibited. Then we silenced snail and found that TGF-β1/TM-induced EMT were also suppressed, but it had no effect on the up-regulated expression of IRE1 and XBP1. Thus, we concluded that IRE1-XBP1 pathway promotes EMT via mediating snail expression in PF. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.